Skip to content
DataLookout
Menu

NCT04476953

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words
    • Primary and study completion pushed from Sep 2026 to Mar 2027
  2. Notable Primary and study completion dates: Sep 2025 to Sep 2026v11
  3. Notable Primary completion date: Dec 2024 to Sep 2025v10
  4. Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv9
  5. Notable Primary completion date: Sep 2023 to Dec 2024
    • Study completion date: Sep 2023 to Sep 2025
    v8
Show 5 earlier versionsHide 5 earlier versions
  1. Notable Primary and study completion dates pushed to Sep 2023v6
  2. Notable Primary completion date: Jan 2022 to Sep 2022
    • Enrollment target: 70 to 80
    • Study completion date: Jul 2022 to Jul 2023
    v5
  3. Minor Primary completion date: Jul 2021 to Jan 2022
    • Study completion date: Jul 2021 to Jul 2022
    v4
  4. Notable Eligibility criteria expanded, about 40 words
    • Secondary endpoint revised
    • Study description shortened, about 6 words
    • Study title revised
    v3
  5. Notable Eligibility criteria expanded, about 400 words
    • Start date changed from estimate of Jul 2020 to Aug 3, 2020
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Serious Adverse Events
Timeframe: 6 months
Change in oxygenation status
Timeframe: baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6

Secondary (1)

CoV Severity Category

Arms and interventions

Treatment GroupExperimental

Subjects will receive treatment drug Fisetin

Placebo GroupPlacebo comparator

Subjects will receive placebo

Drugs: Placebo, Fisetin

Sites

1 site in 1 country

  • Mayo Clinic in RochesterRochester, Minnesota, United States